UNAIDS estimated that there were some ******* people worldwide that died from acquired immune deficiency syndrome (AIDS) in 2024. This statistic depicts the total number of annual AIDS-related deaths worldwide from 2000 to 2024. HIV/AIDS burden A majority of countries with the highest burden due to HIV and AIDS are in Africa- in 2024, the highest number of AIDS-related deaths occurred in South Africa and Mozambique and the highest prevalence of HIV was found in Eswatini. Although access to life-saving antiretroviral therapy treatment (ART) has increased globally over recent years, many individuals living with HIV still lack access to ART. Barriers and interventions In part due to the development of ART, the number of people living with HIV worldwide is continuing to increase, reaching almost ** million in 2024. Important public health measures to combat the burden of the disease include a combination of biomedical and behavioral interventions such as pre- and post-exposure prophylaxis, and context-specific structural interventions to reduce barriers to supplies and education. One prominent barrier faced by those living with HIV is stigma, which can often cause disadvantages in many areas of life, including employment, use of health services, and social support.

The graph depicts the number of AIDS-related deaths in the United States annually from 1981 to 2021. The x-axis represents the years, labeled with two-digit abbreviations from '81 to '21, while the y-axis shows the number of deaths in thousands. Over this 41-year span, AIDS deaths increased dramatically from 1,675.77 in 1981, reaching a peak of 43,276.94 in 1994, and then declined significantly to 6,306.24 by 2021. The data highlights a sharp upward trend in the early years of the epidemic, followed by a substantial downward trend starting in the mid-1990s, reflecting improvements in treatment and prevention. The information is presented in a line graph format, effectively illustrating the rise and subsequent decline in AIDS-related fatalities over the four decades.

HIV/AIDS deaths in the U.S. have dropped significantly in recent years. In 1995, the death rate from HIV per 100,000 people was ****. That number has since decreased to *** per 100,000 as of 2023. The reduction in the HIV death rate in the U.S. can be attributed to an increase in access to HIV medications. HIV/AIDS in the U.S. Human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) cause a systemic viral infection that damages the immune system. AIDS is a syndrome that is caused by HIV. AIDS is when the immune system is severely weakened by HIV and the body can no longer fight off infections. Among all U.S. states, Georgia, followed by Florida and Louisiana, had the highest rates of new HIV diagnoses in 2022. HIV/AIDS treatments in the U.S. HIV/AIDS treatments include antiretroviral medications to reduce the levels of HIV within the body. The largest funders for HIV/AIDS medications and research are the National Institutes of Health (NIH) and the Ryan White Program. The top HIV drug worldwide, based on revenue generated in 2023 was Biktarvy. Around the world, access to antiretroviral treatment has increased dramatically in recent years, a huge step in reducing the number of HIV-related deaths. There is currently no cure for HIV.

this graph was created in Tableu and Ourdataworld :

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2Fc5bb0b21c8b3a126eca89160e1d25d03%2Fgraph1.png?generation=1710708871099084&alt=media" alt="">

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2Ff81fcfa72e97f08202ba1cb06fe138da%2Fgraph2.png?generation=1710708877558039&alt=media" alt="">

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2Fabbdfd146844a7e8d19e277c2eecb83b%2Fgraph3.png?generation=1710708883608541&alt=media" alt="">

Understanding the Global Distribution of HIV/AIDS Deaths

Introduction:

HIV/AIDS remains one of the most significant public health challenges globally, with its impact varying widely across countries and regions. While the overall share of deaths attributed to HIV/AIDS stands at around 1.5% globally, this statistic belies the stark disparities observed on a country-by-country basis. This essay delves into the global distribution of deaths from HIV/AIDS, examining both the overarching trends and the localized impacts across different regions, particularly focusing on Southern Sub-Saharan Africa.

Understanding Global Trends:

At a global level, HIV/AIDS accounts for approximately 1.5% of all deaths. This figure, though relatively low in comparison to other causes of mortality, represents a significant burden on public health systems and communities worldwide. However, when zooming in on specific regions, such as Europe, the share of deaths attributable to HIV/AIDS drops significantly, often comprising less than 0.1% of total mortality. This pattern suggests varying levels of prevalence and effectiveness of HIV/AIDS prevention and treatment strategies across different parts of the world.

Regional Disparities:

The distribution of HIV/AIDS deaths is not uniform across the globe, with certain regions experiencing disproportionately high burdens. Southern Sub-Saharan Africa emerges as a focal point of the HIV/AIDS epidemic, with a significant portion of deaths attributed to the virus occurring in this region. Factors such as limited access to healthcare, socio-economic disparities, cultural stigmatization, and insufficient education about HIV/AIDS contribute to the heightened prevalence and impact of the disease in this area.

Southern Sub-Saharan Africa: A Hotspot for HIV/AIDS Deaths:

Within Southern Sub-Saharan Africa, countries such as South Africa, Botswana, and Swaziland stand out for their exceptionally high rates of HIV/AIDS-related mortality. In these nations, HIV/AIDS can account for up to a quarter of all deaths, highlighting the acute nature of the epidemic in these regions. The reasons behind this disproportionate burden are multifaceted, encompassing issues ranging from inadequate healthcare infrastructure to socio-cultural barriers inhibiting prevention and treatment efforts.

Challenges and Responses:

Addressing the unequal distribution of HIV/AIDS deaths necessitates a multi-faceted approach that encompasses both prevention and treatment strategies tailored to the specific needs of affected communities. Efforts to expand access to antiretroviral therapy (ART), promote comprehensive sexual education, combat stigma, and strengthen healthcare systems are crucial components of an effective response. Moreover, fostering partnerships between governments, civil society organizations, and international entities is essential for coordinating resources and expertise to tackle the HIV/AIDS epidemic comprehensively.

Lessons Learned and Future Directions:

The global distribution of deaths from HIV/AIDS underscores the importance of context-specific interventions that take into account the unique social, economic, and cultural factors influencing the spread and impact of the disease. While progress has been made in reducing HIV/AIDS-related mortality in some regions, much work remains to be done, particularly in areas where the burden of the epidemic remains disproportionately high. Going forward, sustained investment in research, healthcare infrastructure, and community empowerment initiatives will be vital for achieving meaningful reductions in HIV/AIDS deaths worldwide.

Conclusion:

In conclusion, the global distribution of deaths from HIV/AIDS reveals a complex landscape characterized by both overarching trends and localized disparities. While the overall share of deaths attributable to HIV/AIDS may seem relatively modest on a global scale, the stark contrasts observed across different countries and regions underscore the need for targeted interventions tailored to the specific contexts in which the epidemic is most pronounced. By addressing the underlying social, economic, and healthcare-related factors driving the unequal distribution of HIV/AIDS deaths, the global co...

In 2023, India reported an estimate of ** thousand annual AIDS related deaths (ARD) across the country. Male deaths from HIV/AIDS amounted to nearly ** thousand, accounting for approximately ** percent of AIDS related deaths in India that year.

Contents

HIV/AIDS** data from the HIV Surveillance Annual Report * Note: Data reported to the HIV Epidemiology and Field Services Program by June 30, 2016. All data shown are for people ages 13 and older. Borough-wide and citywide totals may include cases assigned to a borough with an unknown UHF or assigned to NYC with an unknown borough, respectively. Therefore, UHF totals may not sum to borough totals and borough totals may not sum to citywide totals."

Dataset has 18 features including:

Year, Borough, UHF, Gender, Age, Race, HIV diagnoses, HIV diagnosis rate, Concurrent diagnoses, % linked to care within 3 months, AIDS diagnoses, AIDS diagnosis rate, PLWDHI prevalence, % viral suppression, Deaths, Death rate, HIV-related death rate, Non-HIV-related death rate

In 2024, the estimated number of deaths from acquired immunodeficiency syndrome (AIDS) in South Africa reached ******. This was slightly higher compared to the previous year, when the AIDS related deaths in the country amounted to ******. From 2006 onwards (except in 2016), the number of AIDS-related deaths dropped annually.

In January 2025, President Trump ordered a pause on funding for the U.S. Agency for International Development (USAID) and a 90-day review of all U.S. foreign assistance. By the end of March, the review had been completed, 83 percent of USAID programs were terminated, and it was announced that certain USAID functions would be overtaken by the Department of State while all others would be discontinued. A preprint research paper posted in April 2025 looked at the possible effects that reductions or cessation of U.S. foreign aid would have on global health. The researchers estimated that the elimination of U.S. foreign aid for global health would result in an additional 15.2 million AIDS-related deaths from 2025 to 2040. Furthermore, they estimated that the loss of U.S. aid would lead to 26.2 million additional HIV infections over this period. This paper has not been peer-reviewed so the estimates should be interpreted with caution, but there is no doubt that such cuts to U.S. foreign aid will result in an increase in HIV infections and deaths, especially in high-impact countries. Trump has said that the United States spends too much on foreign aid and accused USAID of being corrupt and a waste of money. However, foreign aid accounts for just one percent of the federal budget. Furthermore, it is predicted that millions of people will die due to the dissolution of USAID, as vulnerable people around the world will no longer be able to access prevention and treatment for diseases such as HIV/AIDS, tuberculosis, and malaria.

Dataset Overview

The dataset provides a comprehensive look at HIV/AIDS adult prevalence rates, the number of people living with HIV, and annual deaths across different countries. It is based on publicly available data sources such as the CIA World Factbook, UNAIDS AIDS Info, and other global health organizations. The dataset primarily focuses on adult HIV prevalence (ages 15–49) and includes estimates from recent years (e.g., 2023–2024).

Data Science Applications

This dataset can be used for: - Epidemiological Analysis: Understanding the regional distribution of HIV/AIDS and identifying high-prevalence areas. - Predictive Modeling: Developing machine learning models to predict HIV prevalence trends or identify risk factors. - Resource Allocation: Informing policymakers about regions requiring urgent intervention or resource allocation. - Health Outcome Monitoring: Tracking progress in combating HIV/AIDS over time. - Social Determinants Research: Analyzing the relationship between socio-economic factors and HIV prevalence.

Column Descriptors

1. Country/Region: The geographical area being analyzed.
2. Adult Prevalence (%): Percentage of adults aged 15–49 living with HIV.
3. Number of People with HIV/AIDS: Absolute count of individuals living with HIV in the region.
4. Annual Deaths from HIV/AIDS: Number of deaths attributed to HIV/AIDS annually.
5. Year of Estimate: The year when the data was collected or estimated.

Ethically Mined Data

The dataset is ethically sourced from publicly available and credible platforms such as the CIA World Factbook, UNAIDS, and WHO. These organizations ensure transparency and ethical standards in data collection, protecting individual privacy while providing aggregate statistics for research purposes.

Acknowledgments

1. Data Source Platforms:
   • CIA World Factbook
   • UNAIDS AIDS Info
   • WHO Global Health Observatory
2. Dataset Visualization Image:
   • Created using DALL-E 3 for illustrative purposes.
3. Research Support:
   • Contributions from platforms like ResearchGate, NIMH, and others for insights into data science applications in HIV research.

This dataset serves as a valuable tool for researchers, policymakers, and public health professionals in addressing the global challenge of HIV/AIDS.

Data Dictionary JANUARY, 2020 Gender Inequality & HIV/AIDS

Country The country the data corresponds to.The data is a subset of UNICEF’s ‘Key HIV epidemiology indicators for children and adolescents aged 10-19, 1990-2019.’This UNICEF data is sourced from UNAIDS 2020 estimates, which provide ‘modeled estimates using the best available epidemiological and programmatic data to track the HIV epidemic’. Modeled estimates are used because counting the true numbers would require regularly testing entire populations for HIV, and investigating all deaths, which is ‘logistically impossible and ethically problematic.’ For more information on the methodology behind these estimates, see the full UNAIDS 2020 report.

UNICEF Region The region the country belongs to - this dataset includes countries from Eastern & Southern Africa, and West & Central Africa.

Year The year the estimates corresponds to.

Sex Whether the estimates refer to men or women.

Age The age group that the estimates refer to - this dataset contains only estimates for adolescent women and men between the ages of 10-19.

Estimated incidence rate of new HIV infection per 1000 uninfected population The estimated number of new HIV infections, for every 1000 uninfected people in the relevant group. Note - some fields were displayed as ‘<0.01’ in the original data, however these have been rounded up to 0.01 in order to make the field numeric.

Estimated number of annual AIDS related deaths The estimated number of annual AIDS related deaths in the relevant group, to the nearest 100. Note - in the original data, values below 500 were split into the following groups; <500, <200, and <100. To make the field numeric, these have been rounded to 500, 200, and 100 respectively.

Estimated number of annual new HIV infections The estimated number of new annual HIV infections in the relevant group. Note - in the original data, values below 500 were split into the following groups; <500, <200, and <100. To make the field numeric, these have been rounded to 500, 200, and 100 respectively.

The estimated number of people living with HIV in the relevant group. Note - in the original data, values below 500 were split into the following groups; <500, <200, and <100. To make the field numeric, these have been rounded to 500, 200, and 100 respectively.

Estimated rate of annual AIDS related deaths per 100,000 population The estimated number of annual AIDS related deaths, for every 100,000 people in the relevant group. Note - some fields were displayed as ‘<0.01’ in the original data, however these have been rounded up to 0.01 in order to make the field numeric.

Data Source: UNICEF ‘Key HIV epidemiology indicators for children and adolescents aged 10-19, 1990-2019

Dataset

This dataset was created by Josuno

Contents

This dataset provides detailed insights into the prevalence of HIV/AIDS among adults (ages 15–49) across various countries and regions. The data is primarily sourced from the CIA World Factbook and the UNAIDS AIDSinfo platform and reflects the most recent available estimates as of 2022–2024.

What’s Included:

Country/Region – The name of each nation or area.

Adult Prevalence of HIV/AIDS (%) – The percentage of adults estimated to be living with HIV.

Number of People with HIV/AIDS – Estimated count of people infected in each country.

Annual Deaths from HIV/AIDS – Estimated number of HIV/AIDS-related deaths per year.

Year of Estimate – The year the data was reported or estimated.

Key Highlights:

Global Prevalence: Around 0.7% of the global population was living with HIV in 2022, affecting nearly 39 million people.

Hotspots: The epidemic is most severe in Southern Africa, with countries like Eswatini, Botswana, Lesotho, and Zimbabwe reporting adult prevalence rates above 20%.

High Burden Countries:

South Africa: 17.3% prevalence, approximately 9.2 million infected

Tanzania: approximately 7.49 million

Mozambique: approximately 2.48 million

Nigeria: approximately 2.45 million (1.3% prevalence)

Notes:

Data may vary in accuracy and is subject to ongoing updates and verification.

Some entries include a dash ("-") where data was not published or available.

Countries with over 1% adult prevalence are categorized under Generalized HIV Epidemics (GHEs) by UNAIDS.

Context

The New York City Department of Health and Mental Hygiene publishes mid-year and annual HIV surveillance reports each year. This dataset is taken from these reports and includes data gathered from 2011 to June 30, 2016.

Content

This dataset includes HIV infections and AIDS diagnoses, viral suppression in persons living with diagnosed HIV infection (PLWDHI), deaths of those with diagnosed HIV infection, and other statistics from 2011 to 2015 in New York City boroughs.

Purpose

The data contained here shows trends in age, gender, and geographic demographics over time for HIV infections in NYC, and this can be used to visualize the prevalence of the virus in the city.

Acknowledgement

This data was pulled from NYC's OpenData at https://data.cityofnewyork.us/Health/DOHMH-HIV-AIDS-Annual-Report/fju2-rdad .

IntroductionMozambique continues to face a severe HIV epidemic and high cost for its control, largely born by international donors. We assessed feasible targets, likely impact and costs for the 2015–2019 national strategic HIV/AIDS plan (NSP).MethodsThe HIV epidemic and response was modelled in the Spectrum/Goals/Resource Needs dynamical simulation model, separately for North/Center/South regions, fitted to antenatal clinic surveillance data, household and key risk group surveys, program statistics, and financial records. Intervention targets were defined in collaboration with the National AIDS Council, Ministry of Health, technical partners and implementing NGOs, considering existing commitments.ResultsImplementing the NSP to meet existing coverage targets would reduce annual new infections among all ages from 105,000 in 2014 to 78,000 in 2019, and reduce annual HIV/AIDS-related deaths from 80,000 to 56,000. Additional scale-up of prevention interventions targeting high-risk groups, with improved patient retention on ART, could further reduce burden to 65,000 new infections and 51,000 HIV-related deaths in 2019. Program cost would increase from US$ 273 million in 2014, to US$ 433 million in 2019 for ‘Current targets’, or US$ 495 million in 2019 for ‘Accelerated scale-up’. The ‘Accelerated scale-up’ would lower cost per infection averted, due to an enhanced focus on behavioural prevention for high-risk groups. Cost and mortality impact are driven by ART, which accounts for 53% of resource needs in 2019. Infections averted are driven by scale-up of interventions targeting sex work (North, rising epidemic) and voluntary male circumcision (Center & South, generalized epidemics).ConclusionThe NSP could aim to reduce annual new HIV infections and deaths by 2019 by 30% and 40%, respectively, from 2014 levels. Achieving incidence and mortality reductions corresponding to UNAIDS’ ‘Fast track’ targets will require increased ART coverage and additional behavioural prevention targeting key risk groups.

Source: https://en.wikipedia.org/wiki/HIV_adult_prevalence_rate This dataset provides detailed insights into the prevalence of HIV/AIDS among adults (ages 15–49) across various countries and regions 🌐. The data is primarily sourced from the CIA World Factbook and UNAIDS AIDS info platform, and reflects the most recent available estimates as of 2022–2024 📅.

📌 What's Included: Country/Region 🗺️ – The name of each nation or area.

Adult Prevalence of HIV/AIDS (%) 🔬 – The percentage of adults estimated to be living with HIV.

Number of People with HIV/AIDS 👥 – Estimated count of people infected in each country.

Annual Deaths from HIV/AIDS ⚰️ – Estimated number of HIV/AIDS-related deaths per year.

Year of Estimate 📆 – The year the data was reported or estimated.

📈 Key Highlights: Global Prevalence: Around 0.7% of the global population was living with HIV in 2022, affecting nearly 39 million people.

Hotspots: The epidemic is most severe in Southern Africa, with countries like Eswatini, Botswana, Lesotho, and Zimbabwe reporting adult prevalence rates above 20% 🔥.

High Burden Countries:

🇿🇦 South Africa: 17.3% prevalence, ~9.2 million infected.

🇹🇿 Tanzania: ~7.49 million.

🇲🇿 Mozambique: ~2.48 million.

🇳🇬 Nigeria: ~2.45 million (1.3% prevalence).

⚠️ Notes: Data may vary in accuracy and is subject to ongoing updates and verification 🔍.

Some entries include a dash ("-") where data was not published or available ❌.

Countries with over 1% adult prevalence are categorized under Generalized HIV Epidemics (GHEs) by UNAIDS 🚨.

📚 Data Sources: CIA World Factbook 🌐

UNAIDS AIDS Info 💉

Wikipedia 🧠 (used as a collection and compilation point, not primary source)

https://en.wikipedia.org/wiki/HIV_adult_prevalence_rate

Between 2010 and 2024, Eastern Europe and Central Asia was the only region to see an increase in the number of AIDS-related deaths worldwide, with the annual figure increasing by ** percent. Meanwhile, the annual number of AIDS-related deaths declined by 54 percent globally in the same period, with the region of the Caribbean achieving the highest decrease with ** percent.

Background: In 2011 an Investment Framework was proposed that described how the scale-up of key HIV interventions could dramatically reduce new HIV infections and deaths in low and middle income countries by 2015. This framework included ambitious coverage goals for prevention and treatment services resulting in a reduction of new HIV infections by more than half. However, it also estimated a leveling in the number of new infections at about 1 million annually after 2015. Methods: We modeled how the response to AIDS can be further expanded by scaling up antiretroviral treatment (ART) within the framework provided by the 2013 WHO treatment guidelines. We further explored the potential contributions of new prevention technologies: 'Test and Treat', pre-exposure prophylaxis and an HIV vaccine. Findings: Immediate aggressive scale up of existing approaches including the 2013 WHO guidelines could reduce new infections by 80%. A 'Test and Treat' approach could further reduce new infections. This could be further enhanced by a future highly effective pre-exposure prophylaxis and an HIV vaccine, so that a combination of all four approaches could reduce new infections to as low as 80,000 per year by 2050 and annual AIDS deaths to 260,000. Interpretation: In a set of ambitious scenarios, we find that immediate implementation of the 2013 WHO antiretroviral therapy guidelines could reduce new HIV infections by 80%. Further reductions may be achieved by moving to a 'Test and Treat' approach, and eventually by adding a highly effective pre-exposure prophylaxis and an HIV vaccine, if they become available.

Background: The Investment Framework Enhanced (IFE) proposed in 2013 by the Joint United Nations Programme on HIV/AIDS (UNAIDS) explored how maximizing existing interventions and adding emerging prevention options, including a vaccine, could further reduce new HIV infections and AIDS-related deaths in low- and middle-income countries (LMICs). This article describes additional modeling which looks more closely at the potential health impact and cost-effectiveness of AIDS vaccination in LMICs as part of UNAIDS IFE. Methods: An epidemiological model was used to explore the potential impact of AIDS vaccination in LMICs in combination with other interventions through 2070. Assumptions were based on perspectives from research, vaccination and public health experts, as well as observations from other HIV/AIDS interventions and vaccination programs. Sensitivity analyses varied vaccine efficacy, duration of protection, coverage, and cost. Results: If UNAIDS IFE goals were fully achieved, new annual HIV infections in LMICs would decline from 2.0 million in 2014 to 550,000 in 2070. A 70% efficacious vaccine introduced in 2027 with three doses, strong uptake and five years of protection would reduce annual new infections by 44% over the first decade, by 65% the first 25 years and by 78% to 122,000 in 2070. Vaccine impact would be much greater if the assumptions in UNAIDS IFE were not fully achieved. An AIDS vaccine would be cost-effective within a wide range of scenarios. Interpretation: Even a modestly effective vaccine could contribute strongly to a sustainable response to HIV/AIDS and be cost-effective, even with optimistic assumptions about other interventions. Higher efficacy would provide even greater impact and cost-effectiveness, and would support broader access. Vaccine efficacy and cost per regimen are critical in achieving cost-effectiveness, with cost per regimen being particularly critical in low-income countries and at lower efficacy levels.